Watson receives FDA approval for Plan B generic
MORRISTOWN, N.J. Watson Pharmaceuticals on Friday announced that its subsidiary, Watson Labs, has received approval from the Food and Drug Administration regarding its abbreviated new drug application for levonorgestrel (the generic equivalent of Plan B) for over-the-counter use in women ages 17 and above, as well as for prescription use in women under the age of 17.
For the 12-months ended June 30, Plan B had total U.S. sales of approximately $135 million, Watson stated. Watson will market the product under the trade name Next Choice and plans to launch the product shortly.
On June 24, Watson received FDA approval of Next Choice for prescription use. Following this approval, Next Choice is now labeled for both prescription and over-the-counter use, similar to Plan B.
Walgreens announces Pharmacy Management Excellence program with Caterpillar
The news that Walgreens has reached an agreement with Caterpillar to help the company curb healthcare costs for its 70,000 employees, retirees and eligible dependents is one more indicator that the private sector cannot wait for healthcare reform and that pharmacy retailers are taking a greater role on the front lines of health care.
As explained in the article, Walgreens, through its Pharmacy Management Excellence program, will make transparent the prescription drug-pricing model, in turn, eliminating unnecessary and hidden costs for Caterpillar.
Walgreens and Caterpillar are also exploring, through Walgreens Complete Care and Well-Being program, other ways to develop an integrated health care and pharmacy program. The Complete Care and Well-Being program combines worksite health centers, in-store clinics and pharmacies with the discount drug offering
By leveraging its resources, Walgreens is positioning itself along the frontlines of the healthcare and sending the message that retail pharmacy is helping to drive healthcare reform and is a critical player in improving employees’ health and well-being.
As previously mentioned by Drug Store News, the more the private sector leads the way on this, the more likely that reform will work for them, as well as the rest of America.
Neosporin expands with lip care line
NEW YORK Neosporin, a Johnson & Johnson Consumer Cos. brand, is diving into the dry lip segment with the launch of its new Neosporin Lip Health daily hydration therapy and Neosporin Lip Health overnight renewal therapy.
The new products, which are shipping now, will join a portfolio of existing Neosporin products, including Neosporin LT Lip Treatment for the treatment of cold sores and severely dry chapped lips.
The new lip products are clinically shown to restore visibly healthier lips in three days, according to the company.
Neosporin Lip Health daily hydration therapy contains SPF 20 to protect lips from sunburn and both formulas feature a patented combination of lipids and antioxidants to soften and smooth lips. Peptides, vitamins and emollients also help to nourish and strengthen lips over time.
Both products have a suggested retail price of $4.99.